Skip to main content

Table 1 Clinical data of individuals included in cohort I

From: Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers

  NC, n = 42 AD, n = 30
Age (years) 74 ± 6 74 ± 7a
Females (%) 69 70
APOEε4 carriers (%) 38 70
ADAS-Cog (score) 1.88 ± 1.70 8.67 ± 1.90***a
AQT (score) 63.24 ± 10.36 110.18 ± 46.72***a
MMSE (score) 29.19 ± 0.83 19.50 ± 4.27***a
CRP (mg/l) 1.75 ± 1.59 6.94 ± 13.12*a
CSF Aβ40 (pg/ml) 6759.52 ± 1906.93 6452.66 ± 1675.20a
CSF Aβ42 (pg/ml) 791.67 ± 289.29 386.70 ± 110.29***a
CSF p-tau (pg/ml) 45.61 ± 18.16 120.40 ± 41.24***a
CSF t-tau (pg/ml) 341.53 ± 106.23 621.81 ± 207.42***a
Q-albumin 6.75 ± 3.80 6.80 ± 2.54a
  1. amyloid beta, AD Alzheimer’s disease, ADAS-Cog Alzheimer’s Disease Assessment Scale-Cognitive Subscale, APOE4 apolipoprotein 4, AQT A Quick Test, CRP C-reactive protein, CSF cerebrospinal fluid, MMSE Mini-Mental State Examination, NC non-demented control, p-tau phosphorylated tau, t-tau total tau
  2. aData were analysed using either Student’s t-test or Mann-Whitney U-test, and values are presented as mean value ± SD
  3. *Significant at p ≤ 0.05 level
  4. **Significant at p ≤ 0.01 level
  5. ***Significant at p ≤ 0.001 level